KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Net Margin (2016 - 2025)

Jazz Pharmaceuticals has reported Net Margin over the past 15 years, most recently at 16.98% for Q4 2025.

  • Quarterly results put Net Margin at 16.98% for Q4 2025, down 58.0% from a year ago — trailing twelve months through Dec 2025 was 7.82% (down 2162.0% YoY), and the annual figure for FY2025 was 8.33%, down 2214.0%.
  • Net Margin for Q4 2025 was 16.98% at Jazz Pharmaceuticals, down from 22.33% in the prior quarter.
  • Over the last five years, Net Margin for JAZZ hit a ceiling of 22.33% in Q3 2025 and a floor of 68.7% in Q2 2025.
  • Median Net Margin over the past 5 years was 7.89% (2023), compared with a mean of 0.34%.
  • Biggest five-year swings in Net Margin: surged 5248bps in 2022 and later crashed -8516bps in 2025.
  • Jazz Pharmaceuticals' Net Margin stood at 3.61% in 2021, then tumbled by -584bps to 24.69% in 2022, then surged by 138bps to 9.35% in 2023, then skyrocketed by 88bps to 17.56% in 2024, then fell by -3bps to 16.98% in 2025.
  • The last three reported values for Net Margin were 16.98% (Q4 2025), 22.33% (Q3 2025), and 68.7% (Q2 2025) per Business Quant data.